Abstract
Objectives To assess the clinical and economic impact, and cost-effectiveness, of a 2024 Winter and Summer COVID-19 Vaccination Campaign (2024 Vaccination Campaign) in Australia compared to no 2024 Vaccination Campaign.
Design Modelling study using a COVID-19 susceptible-exposed-infect-recovered (SEIR) dynamic transmission model and a COVID-19 vaccination and infections consequences decision analytic model.
Setting, Participants: Australia; Winter 2024 COVID-19 vaccination targeting adults aged ≥18 years, with those aged ≥ 65 years eligible for an additional Summer 2024 dose.
Intervention: 2024 Vaccination Campaign using a Moderna variant-updated mRNA vaccine compared to no 2024 Vaccination Campaign.
Main outcome measures: Projected number of symptomatic infections, hospitalisation, deaths, and cases of long COVID prevented; quality-adjusted life-years (QALYs) gained, incremental cost of the 2024 Vaccination Campaign, and incremental cost-effectiveness ratio (ICER) of the campaign compared to No Vaccination Campaign.
Results Compared to no Vaccination Campaign, a 2024 Vaccination Campaign in Australia is predicted to prevent 241,600 symptomatic infections, 13,500 COVID-19 hospitalisations, 1,200 deaths, and 11,900 cases of long COVID, representing a decrease of 16%, 23%, 26%, and 17%, respectively. This resulted in 19,200 fewer QALYs lost. COVID-19 treatment costs saved with the 2024 Vaccination Campaign was $511.7 million. This partially offset the costs associated with vaccination and adverse event treatment ($1.03 billion), resulting in an incremental 2024 Vaccination Campaign cost of $522 million for a population of 26.3 million, with 4.35 million vaccinations administered. The ICER was $27,100/QALY gained. Increasing the vaccine coverage rate to that observed with influenza vaccination prevented more cases of infection, hospitalisation, and deaths compared to the base case, with an ICER of $34,400/QALY gained.
Conclusion Even in the endemic setting with high hybrid immunity, substantial clinical and economic benefits to vaccinating those aged ≥18 years against COVID-19 remain. These benefits may be amplified with increased vaccination coverage.
Summary box The known: Vaccination campaigns were a cost-effective strategy to battle the clinical and economic impact of COVID-19 during the pandemic. Even in the endemic setting, COVID-19 continues to cause substantial clinical and economic burden to Australia.
The new: Even in a population with high hybrid immunity, COVID-19 vaccination campaigns continue to be cost-effective in Australia in the endemic setting. Clinical benefits are increased by improving the vaccination coverage rate, and not narrowing the targeted population.
The implications: In Australia, annual COVID-19 vaccination campaigns should continue. Increasing the COVID-19 vaccination coverage rates and including a broader recommended population is feasible with an acceptable incremental cost-effectiveness ratio.
Competing Interest Statement
MK is a shareholder in Quadrant Health Economics, Inc., which was contracted by Moderna, Inc. to conduct this study. AL and MM are consultants at Quadrant Health Economics Inc. KJ, EB, PM and EK are employees of Moderna, Inc. and may own stock/stock options in the company.
Funding Statement
This study was funded by Moderna, Inc., Cambridge, MA, USA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.